Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
ATOS is in the long-term down -100% below S&P in 10 years.
Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
|Shares Outstanding||EPS||-2.28||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||18630%||Sales Growth - Q/Q||283.03%||P/E||-0.22|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-112.88%||ROE||-151.51%||ROI|
|Current Ratio||3.26||Quick Ratio||3.23||Long Term Debt/Equity||Debt Ratio||0.34|
|Gross Margin||Operating Margin||-653.31%||Net Profit Margin||-656.04%||Dividend Payout Ratio|
|Cash From Financing Activities||4.29 M||Cash From Investing Activities||-70 K||Cash From Operating Activities||-3 M||Gross Profit||670 K|
|Net Profit||-3.34 M||Operating Profit||-3.28 M||Total Assets||13.8 M||Total Current Assets||11.37 M|
|Total Current Liabilities||3.49 M||Total Debt||110 K||Total Liabilities||3.52 M||Total Revenue||1.87 M|
|High 52 week||7.07||Low 52 week||0.92||Last close||2.54||Last change||0.79%|
|RSI||29.7||Average true range||0.16||Beta||0.87||Volume||177.7 K|
|Simple moving average 20 days||-11.13%||Simple moving average 50 days||-18.15%||Simple moving average 200 days||31.2%|
|Performance Week||-1.93%||Performance Month||-3.05%||Performance Quart||68.21%||Performance Half||96.9%|
|Performance Year||-49.34%||Performance Year-to-date||149.02%||Volatility daily||6.28%||Volatility weekly||14.04%|
|Volatility monthly||28.78%||Volatility yearly||99.7%||Relative Volume||171.06%||Average Volume||3.09 M|
|New High||New Low|
2020-05-28 09:30:10 | Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study
2020-05-07 08:00:10 | Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs
2020-04-22 15:40:26 | Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’
2020-04-16 08:00:10 | Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
2020-04-02 08:00:10 | Atossa Therapeutics Announces Clinical Progress
2020-03-13 08:30:10 | Atossa Therapeutics Announces Upcoming Meeting with FDA
2020-02-05 08:00:10 | Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
2020-01-06 08:00:10 | Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
2019-12-16 11:09:22 | Is Atossa Genetics NASDAQ:ATOS In A Good Position To Deliver On Growth Plans?
2019-12-05 08:30:10 | Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019
2019-10-15 08:30:00 | Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia
2019-07-17 08:30:00 | Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests
2019-06-28 11:38:23 | A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019
2019-06-19 15:56:16 | Some Atossa Genetics NASDAQ:ATOS Shareholders Have Copped A 99% Share Price Wipe Out
2019-05-30 08:00:00 | Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019
2019-04-30 06:10:00 | _The Digital Economy & World Markets_
2019-04-22 08:45:00 | Reducing This Amino Acid May Aid In Fight Against Breast Cancer
2019-03-28 16:30:00 | Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
2019-03-27 10:15:00 | _Bull Market Hopping?_
2019-03-18 08:30:00 | Atossa Genetics Announces Receipt of $10 Million
2019-03-14 13:01:36 | What Type Of Shareholder Owns Atossa Genetics Inc.’s NASDAQ:ATOS?
2019-03-14 12:53:31 | Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing